LCAT and metabolic syndrome: Therefore, we postulate that 27C3(S42A) represents a prototype LCAT antibody therapy for the treatment of dyslipidemia and cardiovascular disease, particularly for patients with clinical manifestations of low HDL syndrome and partial LCAT deficiency, including patients with renal disease.